Imaging neuroinflammation in patients with neurological issues after COVID-19 infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical imaging study aims to visualize and quantify neuroinflammation in individuals suffering from post-acute sequelae of SARS-CoV-2 (PASC) using a specialized PET imaging agent, Fluorodeoxyglucose(18F)-labeled DPA-714. Participants will include both individuals with a clinical diagnosis of PASC and healthy volunteers for comparison. The study will assess the brain uptake of DPA-714 to better understand the neurological effects of COVID-19. The research is designed to provide insights into the neuroinflammatory processes associated with long-term COVID-19 symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 to 65 years of age
2. Healthy volunteer OR Clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)
3. High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.
4. PASC participants must have been previously infected with SARS-CoV-2. Their neurological symptoms must have been present for at least four weeks prior to the enrollment.
5. Healthy control participants must have no neurological symptoms

Exclusion Criteria:

1. Contraindication to MRI
2. Pregnancy
3. Lactation
4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition
5. Chronic infectious disease (e.g. HIV, HCV)
6. Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation
7. Diagnosis of cancer, including leukemia
8. Blood or blood clotting disorder
9. Except for individuals with Multiple Sclerosis (MS), a diagnosis of autoimmune disease is exclusionary
10. Positive urine β-hCG test day of procedure or a serum human chorionic gonadotropin (hCG) test within 48 hours prior to the administration of \[18F\]DPA-714.11.

11Currently enrolled in a clinical trial utilizing experimental therapies. 12. Currently taking experimental therapies 13. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.

The following exclusionary criteria apply only to PASC patients and healthy controls:

14\. Self-reported history of moderate or severe traumatic brain injury 15. Self-reported history of whiplash injury 16. Self-reported history of Inflammatory bowel disease (IBD). (Individuals with Irritable Bowel Syndrome (IBS) and no signs of inflammation will be allowed to participate.) 17. The following blood test results (at screening) will be exclusionary: 18. Rheumatoid Factor (RF) =\> 14 IntUnits/mL, 19. Anti-nuclear antibody (ANA) \> 1:80, 20. Erythrocyte sedimentation rate (ESR) \> 60mm/hour, 21.High sensitivity C-reactive protein (hsCRP) \> 10mg/L, 22. Complete blood count (CBC) results indicating acute infection, anemia, or other condition, 23. T3, T4, or thyroid-stimulating hormone (TSH) levels out of normal range, 24. Fasting glucose \> 100 mg/dL, 25. Blood chemistry results indicating organ damage or other serious medical condition 26. Use of illicit substances within the past 6 months 27. Self-reported diagnosis of Type I or Type II diabetes 28. Healthy controls must not regularly take over-the-counter anti-inflammatory medication, analgesics (except aspirin), or sleep medication

Where it's running

• UAB
  Birmingham, Alabama, United States Recruiting

Study contacts

• Principal investigator: Jonathan McConathy, MD, PhD — University of Alabama at Birmingham
• Study coordinator: April Riddle
• Email: RadiologyCRC@uabmc.edu
• Phone: 205-9961082

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Look at Long COVID after COVID-19

  Researchers will see how common Long COVID is and how symptoms stick around over time in adults who had COVID-19, using questionnaires and saliva samples to look for biological clues.

  Recruiting University of North Carolina, Chapel Hill · Chapel Hill, North Carolina · NCT07781501

• Evaluating antiviral treatments to prevent long-term heart issues after COVID-19

  This study is testing whether antiviral treatments like Paxlovid and Remdesivir can help prevent heart problems in adults who are hospitalized with COVID-19.

  Recruiting Phase 4 Mount Sinai Hospital, Canada · Kingston, Ontario and 3 other locations · NCT06792214

• Cognitive-sensorimotor effects on walking and balance after long COVID

  This project will test whether thinking, vision, sensation, and muscle changes explain walking and balance problems in adults with long COVID.

  Recruiting VA Office of Research and Development · Chicago, Illinois · NCT06850350

• Assessing the impact of COVID-19 on sleep and cognitive health

  This study is trying to see how COVID-19 affects sleep and thinking in people who have recovered from the virus, to better understand long-term health issues they might face.

  Recruiting VA Office of Research and Development · Detroit, Michigan · NCT06291870

• Testing IV saline for cognitive function in POTS and Long COVID patients

  This study is testing whether IV saline can help improve brain fog and mental fatigue in people with POTS and Long COVID.

  Recruiting University of Calgary · Calgary, Alberta · NCT05914649

• Cardiopulmonary rehabilitation for improving function and quality of life in Long COVID

  This trial will try a 12-week cardiopulmonary exercise program to see if it improves symptoms, quality of life, and physical capacity in adults with Long COVID.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT05566483

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.